9MW-2821

Mabwell will present six preclinical studies at the 2025 AACR Annual Meeting in Chicago, highlighting their expanding oncology pipeline with innovative antibody-drug conjugates and T-cell engagers.

Mabwell's 9MW2821, a Nectin-4 targeted ADC, has been granted Breakthrough Therapy Designation (BTD) in China for urothelial carcinoma by the NMPA's Center for Drug Evaluation.

Fujian Guangshengtang Pharmaceutical Co., Ltd. announced that its innovative hepatitis B treatment drug, Neracorvir, has been added to the Breakthrough Therapy List, potentially accelerating its development. This inclusion recognizes the drug's significant clinical advantages and novel antiviral mechanism, distinguishing it from existing treatments.

Intravesical therapies like cretostimogene and TAR-200 show promising complete response rates in BCG-unresponsive NMIBC, but duration of response remains a key factor.

Mabwell's 9MW2821, a novel Nectin-4 targeting antibody-drug conjugate (ADC), has been approved by China's NMPA for two new clinical trials.